- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Management of the T2D Patient With High A1C. (Pubmed Central) - Dec 20, 2020
The speakers discuss the positive outcomes associated with a shorter interval between diagnosis and intensive insulin treatment, and the benefits of timely treatment intensification. They also provide practical advice for counseling patients to achieve an effective transition to injectable medication.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment. (Pubmed Central) - Dec 20, 2020
P2
Once-weekly treatment with insulin icodec had glucose-lowering efficacy and a safety profile similar to those of once-daily insulin glargine U100 in patients with type 2 diabetes. (Funded by Novo Nordisk; NN1436-4383 ClinicalTrials.gov number, NCT03751657.).
- |||||||||| Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Review, Journal: Insulinization in T2DM with Basal Analogues During COVID-19 Pandemic: Expert Opinion from an Indian Panel. (Pubmed Central) - Dec 17, 2020
Practical and easily implementable tips for patients and involvement of stakeholders (caregivers and healthcare providers) to facilitate insulin acceptance were also outlined by the expert panel. Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Similar Breast Cancer Risk in Women Older Than 65 Years Initiating Glargine, Detemir, and NPH Insulins. (Pubmed Central) - Dec 17, 2020
Simplified and convenient insulin regimens like basal insulin analogues are advised during and following the pandemic in order to achieve glycemic control in people with uncontrolled T2DM. Overall, glargine use was not associated with an increased risk of breast cancer compared with NPH or detemir in female Medicare beneficiaries.
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Tresiba (insulin degludec) / Novo Nordisk, Lantus (insulin glargine) / Sanofi
Clinical, Journal, HEOR: Cost-Effectiveness of Insulin Degludec Versus Insulin Glargine U300 in the Netherlands: Evidence From a Randomised Controlled Trial. (Pubmed Central) - Dec 17, 2020
P3
This short-term analysis, informed by the latest clinical trial evidence, demonstrated that degludec was a cost-effective treatment option relative to glargine U300. As such, our modelling analysis suggests that degludec would represent an efficient use of Dutch public healthcare resources in this patient population.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Gla-100 Development: a Story of 'Serendipitous' Disruptive Innovation. (Pubmed Central) - Dec 5, 2020
The superior and unique pharmacological properties, longer duration of action, and significantly lowered risk of hypoglycemia enabled insulin glargine to be distinguished from NPH as a better basal insulin, providing holistic glycemic control. The present review highlights the circumstances that led to the search of truly basal insulins, focusing on the journey of insulin glargine 100 U/mL (Gla-100).
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Two Decades of Gla-100-Reflections from the Pivotal Clinical Trials. (Pubmed Central) - Dec 5, 2020
Further, in trying to achieve fasting normoglycemia, Gla-100 has demonstrated remarkably more holistic glucose-lowering efficacy in several pivotal trials compared to other insulin formulations, such as premixed insulin and coformulations-apart from NPH insulin. This article delineates clinical data on the effectiveness of Gla-100 vs. other insulin formulations in the context of T2DM.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Adoption of Gla-100 in India and its Impact on Insulin Usage Patterns. (Pubmed Central) - Dec 5, 2020
The data from the last 5 years reveal that Gla-100 has gained more traction among Indian clinical practitioners. Basis evidences that have emerged from various clinical studies, this present review elaborates on certain key issues which have helped Gla-100 carve its own niche and effected a progressive shift in insulin prescription pattern in India.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Gla-100 Initiation: The When, Why, and How. (Pubmed Central) - Dec 5, 2020
Insulin glargine 100 U/mL (Gla-100) has been extensively studied under various scenarios as the initial insulin administered early in T2DM disease course, registering significant glycemic and vascular benefits over the standard of care...However, early insulin initiation is mostly delayed owing to 'clinical inertia,' thereby causing an evitable glycemic burden. Therefore, physicians managing diabetes must aim to increase acceptance, persistence, and adherence to insulin therapy by focusing on the safety, simplicity, and convenience of therapies.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Intensification of Gla-100 with Prandial Insulin: A Stepwise Progression Toward Glycemic Control. (Pubmed Central) - Dec 5, 2020
Even though basal insulins, such as insulin glargine 100 U/mL (Gla-100), maintain overall glycemic control, effective PPG control eventually requires intensification of therapy by adding prandial insulins...Owing to such benefits, recent guidelines recommend its use over other approaches for initiating intensification. It is preferred by both physicians and patients and is a better alternative to immediately embarking on a full basal-bolus regimen or introducing premixed insulin preparations for intensification of therapy.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Cardiovascular Safety of Gla-100: Reflections From the ORIGIN and ORIGINALE Trials. (Pubmed Central) - Dec 5, 2020
However, cardiovascular outcome trials (CVOTs) such as the Outcome Reduction with Initial Glargine Intervention (ORIGIN), and its extended follow-up study - ORIGIN and Legacy Effects (ORIGINALE) conclusively established the long-term cardiovascular (CV) safety of basal insulin, such as insulin glargine 100 U/mL (Gla-100)...This review highlights the background developments which led to the ORIGIN trial. Additionally, it also dwells on the critical insights to emerge from this trial pertaining to the CV safety of basal insulin Gla-100 in high CV risk individuals with T2DM.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: In the Spotlight: Role of Gla-100 in the Glycemic Management of Hospitalized people with diabetes. (Pubmed Central) - Dec 5, 2020
Furthermore, a string of clinical studies has also attested to Gla-100 being used effectively even in patients on corticosteroids, enteral or parenteral nutrition, and in perioperative settings. Hence, overall, the existing evidence would point to the growing role of BBI regimens centering around basal insulin like Gla-100 as an effective option with low safety concerns for insulin therapy in both hospitalized and out-patient settings in the treatment of patients with type 2 diabetes mellitus (T2DM).
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Use of Gla-100 in Special Situations. (Pubmed Central) - Dec 5, 2020
This review discusses the various considerations that might guide the decision-making process in the special situations alluded to here. It also throws light on how insulin glargine 100 U/mL has emerged as a preferred choice of insulin therapy in most of these situations, on the strength of its inherently low hypoglycemia and weight gain potential, which has found traction even in the recent diabetes guidelines.
- |||||||||| Lantus (insulin glargine) / Sanofi
[VIRTUAL] Case of Nodular Amyloidosis at Three Insulin Injection Sites in Abdomen () - Dec 2, 2020 - Abstract #ASDP2020ASDP_562;
The patient injects insulin (Lantus) in the area where these are formed...Insulin-derived nodular amyloidosis is underdiagnosed because of the small body of literature in comparison with the prevalence of insulin dependent diabetic patients. Subclinical subcutaneous amyloidosis is probably also more prevalent than reported.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Effect of Different Insulin Therapies on Obstetric-Fetal Outcomes. (Pubmed Central) - Nov 27, 2020
We found no statistically significant differences between the different insulin therapies and the obstetric-fetal outcomes. In conclusión, the different insulin therapies used in patients with pregestational diabetes mellitus does not seem to affect obstetric-fetal outcomes.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Startling hyperglycaemia with transient beta cell stunning in a patient with type 2 diabetes. (Pubmed Central) - Nov 21, 2020
Transient, but total cessation of insulin secretion was documented in a patient with type 2 diabetes under severe metabolic decompensation. Swift, sustained recovery of insulin release indicated that lack of insulin at the time of emergency was due to secretory failure, i.e., unresponsive exocytotic machinery or depletion of releasable insulin, rather than loss of beta cells.
- |||||||||| Lantus (insulin glargine) / Sanofi
[VIRTUAL] INSULIN ALLERGY IN A PATIENT WITH TYPE 1 DIABETES MELLITUS () - Nov 21, 2020 - Abstract #ACAAI2020ACAAI_615;
She was subsequently started on mycophenolate mofetil and a brief course of oral corticosteroids with significant improvement in rash and tolerability of insulin administration.Discussion Evaluation of insulin reactions requires thorough evaluation of non-insulin components and underlying etiology of reaction. Our patient’s clinical history suggested a delayed-type hypersensitivity which is further supported by her clinical improvement with T-cell lymphocyte suppression.
- |||||||||| Lantus (insulin glargine) / Sanofi, Basaglar (insulin glargine biosimilar) / Boehringer Ingelheim, Eli Lilly
Clinical, Journal, HEOR, Real-World Evidence: Real-World Evaluation of Dosing in Patients Converted From Insulin Glargine (Lantus) to Insulin Glargine (Basaglar). (Pubmed Central) - Nov 19, 2020
The estimated monthly acquisition cost of BGlar was significantly less than that for LGlar at conversion ($286 vs $341, P < 0.001) and 6 months ($290 vs $351, P < 0.001) respectively. Conclusion/Relevance: The results of this retrospective study suggest that BGlar resulted in similar glycemic outcomes compared with LGlar in a real-world setting and may be a preferable option in a value-based health care environment.
- |||||||||| Lantus (insulin glargine) / Sanofi
Review, Journal: Drug treatments for managing cystic fibrosis-related diabetes. (Pubmed Central) - Nov 18, 2020
Specifically, investigators should evaluate adherence to different therapies and also whether there is benefit in using additional hypoglycemic agents as well as the newly approved incretin mimics. Agents that potentiate insulin action, especially agents with additional anti-inflammatory potential should also be further investigated as adjuvant therapy to insulin.
- |||||||||| Lantus (insulin glargine) / Sanofi
Journal: Validation of the driver ecological glare test. (Pubmed Central) - Nov 14, 2020
A significant correlation was found between the two glare tests and Bland-Altman analysis reveals a good agreement with a bias of 73.7 arcmin between the halo size measurements obtained from the DEGT and Vision Monitor. The results of the present study demonstrate that the DEGT is a valid method to test halo size and is adapted to evaluate the benefits of an antiglare device for drivers in an ecological situation.
- |||||||||| Soliqua 100/33 (lixisenatide/insulin glargine) / Sanofi
Trial completion: REMIT-iGL: Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IGlarLixi (clinicaltrials.gov) - Nov 13, 2020
P3, N=161, Completed,
The results of the present study demonstrate that the DEGT is a valid method to test halo size and is adapted to evaluate the benefits of an antiglare device for drivers in an ecological situation. Active, not recruiting --> Completed
- |||||||||| Toujeo (Long-acting Recombinant Human Insulin Analogue) / Sanofi, Lantus (insulin glargine) / Sanofi
Journal: GREATER SUPPRESSION OF GLUCAGON, LIPOLYSIS AND KETOGENESIS WITH INSULIN GLARGINE U300 AS COMPARED TO GLARGINE U100 IN TYPE 1 DIABETES MELLITUS. (Pubmed Central) - Nov 7, 2020
Gla-300 resulted in 1) less increase in insulin concentration over 0-12 h, but greater insulin concentration in 12-24 h (no differences over 24 h); 2) greater glucagon suppression; 3) greater prehepatic insulin-to-glucagon molar ratio, primarily in 12-24 h (ratio 1.78, 90%CIs 1.5;2.1); and 4) lower 24 h FFA (0.81; 90%CI 0.73;0.89), glycerol (0.78; 90%CI 0.65;0.94) and -hydroxybutyrate (0.72; 90%CI 0.58;0.90). Over the 24 h post-injection, as compared to Gla-100, clinical doses of Gla-300 exhibit greater suppressive effects on glucagon, lipolysis and ketogenesis, while the effects on glucose metabolism are equivalent.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Journal: Comparison of Hypoglycemia and Safety Outcomes With Long-Acting Insulins Versus Insulin NPH in Pregestational and Gestational Diabetes. (Pubmed Central) - Nov 2, 2020
Objective: To evaluate if insulin glargine or detemir (long-acting insulin) results in less hypoglycemia, hospitalizations, or delivery complications compared with intermediate-acting insulin neutral protamine Hagedorn (NPH) in PGDM and GDM...Conclusion and Relevance: Long-acting insulins did not reduce the frequency of hypoglycemia compared with NPH. The results of this study confirm the need for additional investigations with larger populations.
- |||||||||| Lantus (insulin glargine) / Sanofi
Clinical, Review, Journal: Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients. (Pubmed Central) - Oct 15, 2020
Evidence from existing studies examining the effect of intensive insulin therapy, DPP-4 inhibitors, SGLT inhibitors and glitazones is mostly of low to very low certainty. Appropriately blinded, larger, and higher quality RCTs are needed to evaluate and compare the safety and efficacy of contemporary glucose-lowering agents in the kidney transplant population.
- |||||||||| Lantus (insulin glargine) / Sanofi, Humalog pen (insulin lispro) / Eli Lilly
Trial completion, Trial completion date, Trial primary completion date: REMIT-DM: Remission Through Early Monitored Insulin Therapy - Duration Month (clinicaltrials.gov) - Oct 12, 2020
P4, N=10, Completed,
Appropriately blinded, larger, and higher quality RCTs are needed to evaluate and compare the safety and efficacy of contemporary glucose-lowering agents in the kidney transplant population. Active, not recruiting --> Completed | Trial completion date: Oct 2020 --> Jul 2020 | Trial primary completion date: Oct 2020 --> Jul 2020
|
